Millendo Therapeutics, Inc. MLND, a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that senior management will present company overviews and conduct one-on-one investor meetings at the following healthcare investor conferences:
Citi's 14th Annual Biotech Conference
Date: Thursday, September 5, 2019 (one-on-one meetings only)
Location: Boston, MA
Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies
Date: Monday, September 23, 2019 (one-on-one meetings only)
Location: New York, NY
Ladenburg Thalmann 2019 Healthcare Conference
Date/Time: Tuesday, September 24, 2019 at 11:00 a.m. EDT
Location: New York, NY
A live webcast of the Ladenburg Thalmann presentation will be available on the Investors & Media section of Millendo's website at http://investors.millendo.com. A replay of the webcast will be archived on Millendo's website for 30 days following the presentation.
About Millendo Therapeutics, Inc.
Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo creates distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome, nevanimibe for the treatment of classic congenital adrenal hyperplasia and MLE-301 for the treatment of vasomotor symptoms associated with menopause. For more information, please visit www.millendo.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190829005139/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
